Analyzing OraSure Technologies (OSUR) and FRESENIUS SE &/S (FSNUY)

Share on StockTwits

OraSure Technologies (OTCMKTS: FSNUY) and FRESENIUS SE &/S (OTCMKTS:FSNUY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for OraSure Technologies and FRESENIUS SE &/S, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OraSure Technologies 0 2 1 0 2.33
FRESENIUS SE &/S 1 0 0 0 1.00

OraSure Technologies currently has a consensus price target of $23.50, suggesting a potential upside of 42.68%. Given OraSure Technologies’ stronger consensus rating and higher possible upside, research analysts plainly believe OraSure Technologies is more favorable than FRESENIUS SE &/S.

Dividends

FRESENIUS SE &/S pays an annual dividend of $0.15 per share and has a dividend yield of 0.8%. OraSure Technologies does not pay a dividend.

Insider and Institutional Ownership

95.1% of OraSure Technologies shares are held by institutional investors. Comparatively, 0.1% of FRESENIUS SE &/S shares are held by institutional investors. 2.9% of OraSure Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

OraSure Technologies has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, FRESENIUS SE &/S has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500.

Valuation and Earnings

This table compares OraSure Technologies and FRESENIUS SE &/S’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OraSure Technologies $167.06 million 6.03 $30.94 million $0.51 32.29
FRESENIUS SE &/S $38.28 billion 1.09 $2.05 billion N/A N/A

FRESENIUS SE &/S has higher revenue and earnings than OraSure Technologies.

Profitability

This table compares OraSure Technologies and FRESENIUS SE &/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OraSure Technologies 8.38% 5.85% 5.22%
FRESENIUS SE &/S 5.37% 8.76% 3.52%

Summary

OraSure Technologies beats FRESENIUS SE &/S on 10 of the 14 factors compared between the two stocks.

OraSure Technologies Company Profile

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV?1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, OMNIgene DISCOVER, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, GenoFIND, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, retail pharmacies, mass merchandisers, and consumers. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.

FRESENIUS SE &/S Company Profile

Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis- related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products used in the collection and processing of blood components, as well as in transfusion medicine. The Fresenius Helios segment operates 111 hospitals with approximately 35,000 beds, such as 88 acute care hospitals and 23 post-acute care clinics; 4 post-acute care centers; 17 prevention centers; and 12 nursing homes. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply